Gene silencing and therapeutic targets against Acanthamoeba infections
Jacob Lorenzo-Morales, María Reyes-Batlle, Ines Sifaoui, Atteneri López-Arencibia, Olfa Chiboub, Aitor Rizo-Liendo, Carlos J Bethencourt-Estrella, Francisco Arnalich-Montiel, Pedro Rocha-Cabrera and José E Piñero
from: Protozoan Parasitism: From Omics to Prevention and Control (Edited by: Luis Miguel de Pablos Torró and Jacob-Lorenzo Morales). Caister Academic Press, U.K. (2018) Pages: 171-178.
Pathogenic strains of Acanthamoeba genus are the causative agents of a sight threating infection of the cornea known as Acanthamoeba keratitis (AK). The incidence of AK has risen worldwide in the recent years which is highly related to an increase in the number of contact lens wearers, the main group of individuals at risk. Moreover, due to the ability of these amoebae to form a highly resistant cyst stage, most of the currently available treatments and contact lens maintenance solutions are not fully effective. The development of Acanthamoeba genome project, releasing the sequences of the whole genome of this pathogen as well as the availability of novel therapeutic approaches such as gene silencing using RNAi technology, has allowed the application of this approach for the elucidation of novel drug targets in Acanthamoeba. In this chapter, the advances in this field as well as current and future therapeutic approaches against AK are described read more ...